Journal: International Journal of Nanomedicine

Article Title: A Three-Dimensional Printed Polycaprolactone Scaffold Combined with Co-Axially Electrospun Vancomycin/Ceftazidime/Bone Morphological Protein-2 Sheath-Core Nanofibers for the Repair of Segmental Bone Defects During the Masquelet Procedure

doi: 10.2147/IJN.S238478

Figure Lengend Snippet: SEM image and fiber diameter distribution of ( A ) pure PLGA nanofibers, ( B ) sheath-core PLGA/BMP-2 nanofibers, and ( C ) PLGA/vancomycin/ceftazidime nanofibers.

Article Snippet: Commercial antibodies were adapted for IHC analysis; these included anti-BMP-2 (polyclonal, 1:200; cat. no. A0231; ABclonal, MA, USA); anti-VEGF (polyclonal, 1:200; cat. no. A0280; ABclonal); anti-vWF (vWF Picoband antibody, 1:200; cat. no. PB9062; Boster Biological Technology, Pleasanton CA, USA); anti-TGF-β (polyclonal, 1:200; cat. no. A2561; ABclonal); and anti-IL-6 (polyclonal, 1:200; cat. no. A0286; ABclonal).

Techniques:

Journal: International Journal of Nanomedicine

Article Title: A Three-Dimensional Printed Polycaprolactone Scaffold Combined with Co-Axially Electrospun Vancomycin/Ceftazidime/Bone Morphological Protein-2 Sheath-Core Nanofibers for the Repair of Segmental Bone Defects During the Masquelet Procedure

doi: 10.2147/IJN.S238478

Figure Lengend Snippet: Water contact angles of ( A ) pure PLGA nanofibers (126.24 ± 10.26°), ( B ) sheath-core PLGA/BMP-2 nanofibers (120.00 ± 8.67°), and ( C ) PLGA/vancomycin/ceftazidime nanofibers (69.2.33 ± 5.14°). Substantially improved hydrophilicity of electrospun nanofibers was observed with the addition of water-soluble antibiotics.

Article Snippet: Commercial antibodies were adapted for IHC analysis; these included anti-BMP-2 (polyclonal, 1:200; cat. no. A0231; ABclonal, MA, USA); anti-VEGF (polyclonal, 1:200; cat. no. A0280; ABclonal); anti-vWF (vWF Picoband antibody, 1:200; cat. no. PB9062; Boster Biological Technology, Pleasanton CA, USA); anti-TGF-β (polyclonal, 1:200; cat. no. A2561; ABclonal); and anti-IL-6 (polyclonal, 1:200; cat. no. A0286; ABclonal).

Techniques:

Journal: International Journal of Nanomedicine

Article Title: A Three-Dimensional Printed Polycaprolactone Scaffold Combined with Co-Axially Electrospun Vancomycin/Ceftazidime/Bone Morphological Protein-2 Sheath-Core Nanofibers for the Repair of Segmental Bone Defects During the Masquelet Procedure

doi: 10.2147/IJN.S238478

Figure Lengend Snippet: In vitro drug release profiles. ( A ) Daily and ( B ) accumulated release of antibiotics from the composite nanofibers. ( C ) Daily and ( D ) accumulated release of BMP-2 from the composite nanofibers. In vivo examination of the daily release of ( E ) antibiotics and ( F ) BMP-2 from the composite scaffold in the muscular tissue.

Article Snippet: Commercial antibodies were adapted for IHC analysis; these included anti-BMP-2 (polyclonal, 1:200; cat. no. A0231; ABclonal, MA, USA); anti-VEGF (polyclonal, 1:200; cat. no. A0280; ABclonal); anti-vWF (vWF Picoband antibody, 1:200; cat. no. PB9062; Boster Biological Technology, Pleasanton CA, USA); anti-TGF-β (polyclonal, 1:200; cat. no. A2561; ABclonal); and anti-IL-6 (polyclonal, 1:200; cat. no. A0286; ABclonal).

Techniques: In Vitro, In Vivo

Journal: International Journal of Nanomedicine

Article Title: A Three-Dimensional Printed Polycaprolactone Scaffold Combined with Co-Axially Electrospun Vancomycin/Ceftazidime/Bone Morphological Protein-2 Sheath-Core Nanofibers for the Repair of Segmental Bone Defects During the Masquelet Procedure

doi: 10.2147/IJN.S238478

Figure Lengend Snippet: Analysis of the gross specimen ( A ) revealed a thick induced membrane (IM) formed circumferentially around the applied scaffold. The PLGA nanofibers had been dissolved completely, and only the PCL mesh was preserved. The histological evaluation of the induced membrane was performed (blue arrow) and represents in ( B ). ( B ) Histological evaluation by hematoxylin and eosin staining of the induced membrane. Radiographic examination of fracture healing in ( C ) the PCL group, ( D ) the PCL-PLGA/antibiotic group, and ( E ) the PCL-PLGA/antibiotic/BMP-2 group.

Article Snippet: Commercial antibodies were adapted for IHC analysis; these included anti-BMP-2 (polyclonal, 1:200; cat. no. A0231; ABclonal, MA, USA); anti-VEGF (polyclonal, 1:200; cat. no. A0280; ABclonal); anti-vWF (vWF Picoband antibody, 1:200; cat. no. PB9062; Boster Biological Technology, Pleasanton CA, USA); anti-TGF-β (polyclonal, 1:200; cat. no. A2561; ABclonal); and anti-IL-6 (polyclonal, 1:200; cat. no. A0286; ABclonal).

Techniques: Staining

Journal: International Journal of Nanomedicine

Article Title: A Three-Dimensional Printed Polycaprolactone Scaffold Combined with Co-Axially Electrospun Vancomycin/Ceftazidime/Bone Morphological Protein-2 Sheath-Core Nanofibers for the Repair of Segmental Bone Defects During the Masquelet Procedure

doi: 10.2147/IJN.S238478

Figure Lengend Snippet: Immunohistochemical analysis of the expression of ( A ) BMP-2 (*membrane-lining cells, † spindle cells), ( B ) TGF-β (*membrane-lining cells, † spindle cells), ( C ) vWF, ( D ) VEGF, and ( E ) IL-6.

Article Snippet: Commercial antibodies were adapted for IHC analysis; these included anti-BMP-2 (polyclonal, 1:200; cat. no. A0231; ABclonal, MA, USA); anti-VEGF (polyclonal, 1:200; cat. no. A0280; ABclonal); anti-vWF (vWF Picoband antibody, 1:200; cat. no. PB9062; Boster Biological Technology, Pleasanton CA, USA); anti-TGF-β (polyclonal, 1:200; cat. no. A2561; ABclonal); and anti-IL-6 (polyclonal, 1:200; cat. no. A0286; ABclonal).

Techniques: Immunohistochemical staining, Expressing

Journal: Neural Regeneration Research

Article Title: Effect of glycosides of Cistanche on the expression of mitochondrial precursor protein and keratin type II cytoskeletal 6A in a rat model of vascular dementia

doi: 10.4103/1673-5374.211196

Figure Lengend Snippet: Effect of GCs on p-tau and Aβ immunoreactivity in the hippocampus of a rat model of vascular dementia. (A–F) Representative immunohistochemical images for p-tau and Aβ staining. Cells immunopositive for p-tau (A–C) and Aβ (D–F) in control (A, D), vascular dementia model (B, E), and GC-treated (C, F) rats. Black arrows indicate immunopositive cells, with orange-brown staining in the cytoplasm indicating p-tau and Aβ imunoreactivity. (G) Average gray values of p-tau and Aβ in control rats, vascular dementia rats and CG-treated rats. p-tau and Aβ immunoreactivity was greater in the vascular dementia group than in the control group. This upregulation was significantly decreased after treatment with GC. Data are expressed as the mean ± SD. * P < 0.05, # P < 0.05 (two-way analysis of variance). Experiments were conducted in triplicate. GC: Glycosides of Cistanche ; p-tau: phosphorylated tau; Aβ: amyloid beta; VD: vascular dementia.

Article Snippet: Sections were then incubated in rabbit anti-rat phosphorylated p-tau primary antibody (1:1,000 in PBS; Bioworld Technology, Inc., TX, USA) and rabbit anti-rat amyloid beta (Aβ) primary antibody (1:1,000; Bioworld Technology, Inc.) in a wet box at 37°C for 2–3 hours, before incubation in the secondary antibody (goat anti-mouse IgG; Bioworld Technology, Inc.) for 15 minutes at room temperature.

Techniques: Immunohistochemical staining, Staining